Is pancreatic cancer survival improving? — what has actually changed

People ask this question at two moments. The first is in the days after a diagnosis, when the search results are frightening and every page seems to say the same bleak thing. The second is later, when a treatment decision is being weighed and it matters whether the effort is worth it. The honest answer to is pancreatic cancer survival improving is yes — slowly, unevenly, and by less than this disease deserves. It is a real improvement and it is not a transformation. You are owed both halves of that sentence.

Nearly all of the movement has come from treatment, and from how carefully patients are matched to it. Very little of it has come from finding the disease sooner. There is still no simple test that catches a pancreatic tumour in a well person, and most tumours are still found after they have grown into the vessels behind the pancreas or spread beyond them. That single fact holds the headline figures down, and it will keep holding them down until early detection changes.

The second thing worth knowing is how slowly any of this reaches the numbers you can read. A survival rate needs years of follow-up before it can be calculated at all, so a figure published today describes people diagnosed and treated well before the treatment now being offered to you. Pancreatic cancer survival by stage, and how to read those numbers takes that apart properly, stage by stage.

The rest of this page is specific: what has genuinely moved, what has not moved at all, and how either fact bears on one person’s plan rather than on an average. If you want the wider picture first, the complete pancreatic cancer guide covers diagnosis, treatment and support in one place.

• It is still usually found late. The early symptoms — vague upper abdominal ache, unexplained weight loss, pale stools, a change in appetite — belong to a dozen harmless conditions as well. Painless jaundice is the one exception that warrants a check the same week.
• There is no screening test for the general population. Surveillance is offered only to defined high-risk groups, such as people with an inherited cancer syndrome or a strong family pattern, and it is done with MRI/MRCP or endoscopic ultrasound rather than with a blood test.
• CA 19-9 is not a screening test. It is useful for following a tumour that is already known about, and misleading when used to go looking for one. It rises in ordinary bile-duct obstruction, and in some people it never rises at all.
• Not everyone can take the treatments that improved the figures. Combination chemotherapy demands a level of fitness and organ function. Much of the improvement in group statistics belongs to the people who were able to complete it.
• Published figures lag by years, by construction. Any five-year rate has to describe an older era of care, because five years had to pass before it could be worked out. Today’s number is not today’s medicine.
• A trend is not a promise. An improving average tells you the field is moving. It says nothing about what will happen to one person, which turns on resectability, tumour type, tumour biology and general health.

1. 1

   Confirm what the tumour actually is

   Adenocarcinoma and neuroendocrine tumour are different diseases with different outlooks, and the published figures for one do not describe the other. Tissue is usually taken by endoscopic ultrasound with a fine-needle sample.

   Biopsy coordinated with specialist endoscopy partners
2. 2

   Establish the resectability category

   A pancreatic-protocol contrast CT is read specifically for the tumour’s relationship to the arteries and veins behind the pancreas. That reading decides whether an operation is on the table now, later, or not at all.

   Ordered and reported in-house at CION
3. 3

   Test, because testing now changes the options

   Germline testing is offered whatever the family history, and tumour profiling where the disease is locally advanced or metastatic. Counselling comes with it, for you and for the relatives the result may concern.

   Genetic counselling in-house at CION
4. 4

   Sequence the treatment deliberately

   Where a tumour sits at the borderline, systemic treatment goes first and the vessels are reassessed afterwards, with chemoradiation or SBRT used where it helps. Any operation that follows is arranged with partner surgeons.

   Systemic therapy and radiation in-house; surgery coordinated
5. 5

   Protect the ability to keep treating

   Enzyme replacement, nutrition, pain control and psycho-oncology run alongside from the first week, because the treatments that improved the outcomes only help the people who can finish them.

   Free 45-minute consultation

Your first consultation is free and lasts 45 minutes, and it is a genuine reading of your reports rather than a booking appointment. Being clear about where each part of care happens saves a difficult conversation later.

Delivered in-house at CION, across 35+ centres in Telangana and Andhra Pradesh: medical oncology — chemotherapy before surgery, after surgery and for advanced disease; PARP-inhibitor-class maintenance where an inherited BRCA change is found; immune checkpoint inhibitor therapy where the tumour is mismatch-repair deficient; and systemic treatment for neuroendocrine tumours, including somatostatin-analogue-class therapy. Also radiation, chemoradiation and SBRT; the ordering and reporting of pancreatic-protocol CT, MRI/MRCP, CA 19-9 and bloods; genetic counselling; nutrition and pancreatic enzyme replacement; pain relief, psycho-oncology and supportive care; and survivorship follow-up.

Coordinated with specialist HPB, gastroenterology and endoscopy partner centres, and may be billed there: all pancreatic surgery, including the Whipple procedure and distal pancreatectomy; endoscopic ultrasound with biopsy; ERCP and biliary or duodenal stenting; staging laparoscopy; coeliac plexus block for pain; PET-CT and DOTATATE PET; and peptide receptor radionuclide therapy. We arrange these, we sit in on the decisions, and we tell you in advance where each one happens and who invoices you. Several of the surgical and endoscopic advances described on this page belong to those partner centres, and we do not claim them as our own theatre or endoscopy lists.

So the improvement is real and it is incremental. Cure remains possible when a tumour is found early and removed completely. Systemic treatment can move a borderline tumour into the operable group. Neuroendocrine tumours have always carried a better outlook. And the testing that steers treatment is now offered to everyone with the diagnosis rather than to a few. None of that is a promise to any one person, and all of it is a reason to have the specific conversation instead of settling for the average.

Medical disclaimer: This page describes how and where pancreatic cancer outcomes have improved, and is reviewed by a CION medical oncologist with reference to NCCN guidance on pancreatic adenocarcinoma. It is general information and deliberately states no survival figure, because no published figure describes an individual; your own outlook depends on your resectability category, tumour type, tumour biology and general health, and should be discussed with your treating team. Chemotherapy, radiation, chemoradiation and SBRT, imaging and CA 19-9 ordering and reporting, genetic counselling, nutrition and enzyme support, pain relief, psycho-oncology and survivorship care are delivered by CION; all pancreatic surgery, endoscopic ultrasound and biopsy, ERCP and stenting, staging laparoscopy, coeliac plexus block, PET-CT and DOTATATE PET, and peptide receptor radionuclide therapy are coordinated with specialist HPB, gastroenterology and endoscopy partner centres and may be billed there.